Preferred test for fresh specimens at time of diagnosis for detecting prognostically important genomic abnormalities in leukemias/lymphomas and solid tumors involving loss/gain of DNA or loss of heterozygosity (LOH). Monitor disease progression and response to therapy.
Genomic Microarray (Oligo-SNP Array)
New York DOH Approval Status
Green (sodium heparin). Bone marrow or peripheral blood required.
Transport 3 mL bone marrow. (Min: 1 mL) or 5 mL peripheral blood (Min: 2 mL)
Frozen specimens. Clotted specimens.
Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Refer to report
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
This test must be ordered using a Cytogenetic test request form 43099 or through your ARUP interface.
|Component Test Code*||Component Chart Name||LOINC|
|2006326||Cytogenomic Microarray SNP - Oncology|
|2006327||EER CMA ONC||11526-1|
- genomic microarray, oligo-SNP array